This article provides an overview of ALK-positive non-small cell lung cancer and the types of molecular tests carried out to diagnose the disease. Lung cancer nurse specialists’ role in the treatment pathway is also discussed, as well as the guidance they can provide to help patients understand their diagnosis and its implications.
Cancer Nursing Practice. 15, 10, 26-28. doi: 10.7748/cnp.2016.e1364b
CorrespondenceDiana.Borthwick@nhslothian.scot.nhs.uk
Peer reviewThis article has been subject to external double-blind peer review and checked for plagiarism using automated software
Conflict of interestThis supplement has been commissioned and paid for by Novartis. Novartis has funded medical writing support through Nyxeon Healthcare Communications and payment to the journal for advertorial space. All authors contributed equally to the development, design and review of this article; Novartis has reviewed and approved the content
Received: 30 September 2016
Accepted: 07 November 2016
or
Alternatively, you can purchase access to this article for the next seven days. Buy now
Are you a student? Our student subscription has content especially for you.
Find out more
